Postinflammatory hyperpigmentation
L’Postinflammatory hyperpigmentation hè una cundizione cutanea caratterizzata da un pigmentu aumentatu in a pelle dopu à l’infiammazione. Pò esse causata da l’esposizione prolungata à u sole, da infiammazioni, o da altre ferite di a pelle, cumprese quelle ligate à l’acne. E persone cù toni di pelle scura sò generalmente più propense à l’iperpigmentazione per via di l’excès di sole.
☆ AI Dermatology — Free Service
In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
relevance score : -100.0%
ReferencesPostinflammatory hyperpigmentation (PIH) hè un prublema di a pelle frequente chì succede dopu l’infiammazione di a pelle o ferite. Tende à durà assai tempu è hè più grave in e persone cù tonalità di pelle più scura (Fitzpatrick skin types III–VI). Ancu s'ellu spessu si risolve da solu, pò piglià un pocu di tempu; dunque u trattamentu hè spessu necessariu per ottene un risultatu soddisfacente. Cumminà diversi trattamenti funziona megliu.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation hè una sequenza cumuni di inflammazioni di a pelle. Tende à affettà l'individui di a pelle scura più severamente è più spessu. I studii mostranu chì i prublemi cum'è postinflammatory hyperpigmentation sò trà i mutivi principali per chì e persone cù tonalità di pelle scura cercanu cura dermatologica. U trattamentu precoce hè cruciale per risolve postinflammatory hyperpigmentation è di solitu principia cù a gestione di a cundizione infiammatoria iniziale. A prima linea di trattamentu tipicamenti implica l'usu di l'agenti topichi chì illuminanu a pelle cù u sunscreen per a prutezzione. Questi agenti, cum'è hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts, ponu efficacemente riduce a pigmentazione eccessiva. Inoltre, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy sò ancu usati cum'è agenti depigmentanti, cù novi trattamenti emergenti. Mentre i trattamenti topichi sò generalmente efficaci per l'iperpigmentazione à u livellu di a superficia, i prucessi (laser, chemical peel) ponu esse necessarii per i casi persistenti. Hè impurtante piglià prudenza cù questi trattamenti per evità l'irritazione è l'aggravamentu di postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
